Clinical trials: Precision Treatment
Primary Liver Cancer
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation
The objective of this study is to assess the safety and efficacy of DC Bead™ delivered by intra-arterial embolisation for the treatment of Hepatocellular Carcinoma
- Trial name
- PRECISIONV (NCT00261378)
- Testing
- Transarterialchemoembolisation (TACE), DC Bead with Doxorubicin
- Where
- 17 sites in Austria, France and 2 more
- Volunteers
- 212 people
- Sponsor
- Boston Scientific Corporation
Rare Tumor, Refractory Tumor
Efficacy and Safety of Precision Therapy in Refractory Tumor
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
- Trial name
- NCT03239015
- Testing
- Gefitinib, Erlotinib, Afatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Baodong Qin
Fetal Hydrops
Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment
Based on multi-center clinical research resources, a large-scale prospective cohort study will be conduted to make a more accurate diagnosis and intervention plan of Non-immune fetal hydrops (NIFH), and then establish NIFH…
- Trial name
- NCT02956564
- Testing
- intrauterine intervention
- Volunteers
- 144 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Triple-negative Breast Cancer
Reverse Triple Negative Immune Resistant Breast Cancer
This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with…
- Trial name
- Renaissance (NCT05076682)
- Testing
- Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fudan University
Carcinoma, Solid Tumor
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid…
- Trial name
- NCT06112041
- Testing
- ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Type 1 Diabetes, T1D Heart Failure
Precision T1D Platform - New Therapies for Cardio-Renal Complications
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D.
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Trial name
- NCT07594145
- Testing
- Finerenone, Sotagliflozin
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Oregon Health and Science University
Suicidal Ideation
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm).
- Trial name
- PRE-EMPT (NCT07484906)
- Testing
- fMRI Neurofeedback, Accelerated theta burst stimulation, Psilocybin assisted therapy
- Sponsor
- University of New Mexico
Takayasu Arteritis
A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
This study aimed to compare the efficacy and safety of a precision treatment regimen based on clinical-molecular phenotypes with a conventional treatment regimen in the treatment of patients with active Takayasu's arteritis based…
- Trial name
- NCT06498089
- Testing
- Prednisone, Methotrexate, Tocilizumab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumor Cancer, Primary CNS Tumors
The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions.
A total of 550 patients with metastatic solid tumors or primary CNS malignancy will be recruited on a first come first serve basis at one of the 14 participating centers : UZL, UZG, Imelda, ZAZ, AZ Klina, CHU Liège, GHdC, CHU UCL…
- Trial name
- GeNeo2 (NCT07713550)
- Testing
- Comprehensive NGS testing
- Where
- 14 sites in Belgium
- Volunteers
- 550 people
- Sponsor
- The Belgian Society of Medical Oncology
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Peripheral T-cell Lymphoma (PTCL)
New Genotype-guided Treatment in Newly Diagnosed PTCL
This is a phase I/II study evaluate the safety and efficacy targeted agents in combination with standard CHOP in new genotypic subtypes in treatment naive peripheral T-cell lymphoma. Phase I is to confirm RP2D of targeted agent.
- Trial name
- G08 (NCT07706959)
- Testing
- Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Adjuvant Drug Therapy
The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER
In Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years…
- Trial name
- POWER (NCT07502820)
- Testing
- Individual dose of tamoxifen, Standard adjuvant therapy of tamoxifen
- Where
- 4 sites in Sweden
- Volunteers
- 1,100 people
- Sponsor
- Karolinska Institutet
Esophageal Cancer, Esophageal Adenocarcinoma
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
Background: The number of patients with esophageal cancer keeps rising. For many patients, a combination of surgery, chemotherapy, and radiation is necessary to completely treat the disease.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms
- Trial name
- NCT03223662
- Testing
- Chemoradiotherapy, Esophagectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cholangiocarcinoma (Part 1)
A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping
This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.
- Trial name
- NCT07164703
- Testing
- Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Mao-Lin Yan
Disorders of Consciousness, Vegetative State
AI-Assisted Precision Hyperbaric Oxygen Therapy Based on Dynamic BIS-EEG Feedback for Patients With Disorders of Consciousness
Disorders of consciousness (DoC) are severe neurological conditions characterized by impaired awareness and reduced interaction with the environment.
- Conditions
- Disorders of Consciousness, Vegetative State, Minimally Conscious State
- Trial name
- AI-HBOT-DoC (NCT07855848)
- Testing
- AI-Assisted Personalized Hyperbaric Oxygen Therapy, Conventional Hyperbaric Oxygen Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Smoking Cessation, Smoking
Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting.
- Conditions
- Smoking Cessation, Smoking, Physician's Role
- Trial name
- PROMISE (NCT07166120)
- Testing
- Usual care, Precision treatment
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Washington University School of Medicine
Autism Spectrum Disorder
Precision TMS Treatment Guided by Personalized Brain Functional Sectors (pBFS) for ASD
This study will evaluate the efficacy and safety of pBFS-guided TMS treatment for the core symptom in autism spectrum disorder children, adolescents and young adults.
- Trial name
- NCT05890846
- Testing
- active iTBS, traditional 1on1 course
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Changping Laboratory
Breast Cancer, Breast Cancer (Triple Negative Type)
Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded…
- Trial name
- SENOCOHORT (NCT07833891)
- Testing
- Patients follow-up
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment
Pear Bio has developed an organ-on-a-chip device together with a computer vision pipeline through which the response of an individual patient's tumor to different chemotherapy regimens can be tested simultaneously ex vivo.
- Trial name
- PEAR-TNBC (NCT05435352)
- Testing
- Core needle biopsy
- Where
- 3 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Ourotech, Inc.